cantab pharmaceuticals biotechnology company begun new round trials kidney transplant drug writes daniel green the trials first placebocontrolled phase ii designed assess well drug works if go well would put much larger phase iii trials approval product launch 1997 the drug developed baxter international us healthcare company the drug codenamed lmcd45 designed reduce chance newly transplanted kidney rejected patient lmcd45 holds promise reducing frequency acute rejection thereby improving success rate costeffectiveness transplant procedure said mr don joseph president baxters renal division mr paul haycock chief executive said company investigating use drug prevent rejection transplants organs